XML 65 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Revenues
 12 Months Ended
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Product Revenues
Revenues by product are summarized as follows:
 For the Years Ended December 31,
 202020192018
(In millions)United
States		Rest of
World		TotalUnited
States		Rest of
World		TotalUnited
States		Rest of
World		Total
Multiple Sclerosis (MS):
Fumarate*$2,742.0 $1,163.4 $3,905.4 $3,312.0 $1,126.2 $4,438.2 $3,253.2 $1,020.9 $4,274.1 
Interferon**1,273.5 604.0 1,877.5 1,426.6 675.2 2,101.8 1,668.3 694.7 2,363.0 
TYSABRI1,096.8 849.3 1,946.1 1,041.8 850.4 1,892.2 1,025.0 839.0 1,864.0 
FAMPYRA— 103.1 103.1 — 97.1 97.1 — 92.7 92.7 
ZINBRYTA— — — — — — — 1.4 1.4 
Subtotal: MS5,112.3 2,719.8 7,832.1 5,780.4 2,748.9 8,529.3 5,946.5 2,648.7 8,595.2 
Spinal Muscular Atrophy:
SPINRAZA787.8 1,264.3 2,052.1 933.4 1,163.6 2,097.0 854.0 870.2 1,724.2 
Biosimilars:
BENEPALI— 481.6 481.6 — 486.2 486.2 — 485.2 485.2 
IMRALDI— 216.3 216.3 — 184.0 184.0 — 16.7 16.7 
FLIXABI— 97.9 97.9 — 68.1 68.1 — 43.2 43.2 
Subtotal: Biosimilars— 795.8 795.8 — 738.3 738.3 — 545.1 545.1 
Other:
FUMADERM— 12.2 12.2 — 15.2 15.2 — 22.3 22.3 
Total product revenues$5,900.1 $4,792.1 $10,692.2 $6,713.8 $4,666.0 $11,379.8 $6,800.5 $4,086.3 $10,886.8 
*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.
**Interferon includes AVONEX and PLEGRIDY.
We recognized revenues from two wholesalers accounting for 30.5% and 15.3% of gross product revenues in 2020, 30.0% and 17.2% of gross product revenues in 2019 and 32.0% and 18.4% of gross product revenues in 2018, respectively.
As of December 31, 2020, two wholesale distributors individually accounted for approximately 21.1% and 8.5% of net accounts receivable associated with our product sales, as compared to 24.1% and 13.9% as of December 31, 2019, respectively.
An analysis of the change in reserves for discounts and allowances is summarized as follows:
December 31, 2020
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Beginning balance$131.1 $1,027.3 $40.5 $1,198.9 
Current provisions relating to sales in current year774.7 3,308.8 19.0 4,102.5 
Adjustments relating to prior years(1.0)(54.0)1.3 (53.7)
Payments/returns relating to sales in current year(635.1)(2,426.1)— (3,061.2)
Payments/returns relating to sales in prior years(128.3)(763.0)(19.2)(910.5)
Ending balance$141.4 $1,093.0 $41.6 $1,276.0 
December 31, 2019
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Beginning balance$127.8 $888.8 $34.7 $1,051.3 
Current provisions relating to sales in current year666.2 3,011.5 20.9 3,698.6 
Adjustments relating to prior years0.3 (54.1)5.5 (48.3)
Payments/returns relating to sales in current year(535.5)(2,242.9)(0.2)(2,778.6)
Payments/returns relating to sales in prior years(127.7)(576.0)(20.4)(724.1)
Ending balance$131.1 $1,027.3 $40.5 $1,198.9 
December 31, 2018
(In millions)DiscountsContractual
Adjustments		ReturnsTotal
Beginning balance$109.6 $606.0 $46.0 $761.6 
Current provisions relating to sales in current year679.3 2,686.7 23.1 3,389.1 
Adjustments relating to prior years(0.3)(10.0)(1.8)(12.1)
Payments/returns relating to sales in current year(551.7)(1,887.6)(1.1)(2,440.4)
Payments/returns relating to sales in prior years(109.1)(506.3)(31.5)(646.9)
Ending balance$127.8 $888.8 $34.7 $1,051.3 
The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:
 As of December 31,
(In millions)20202019
Reduction of accounts receivable$195.4 $197.8 
Component of accrued expenses and other1,080.6 1,001.1 
Total revenue-related reserves$1,276.0 $1,198.9 
Revenues from Anti-CD20 Therapeutic Programs
Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 For the Years Ended December 31,
(In millions)202020192018
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA$1,080.2 $1,542.4 $1,431.9 
Other revenues from anti-CD20 therapeutic programs897.6 748.0 548.3 
Total revenues from anti-CD20 therapeutic programs$1,977.8 $2,290.4 $1,980.2 
Approximately 14.7%, 15.9% and 14.7% of our total revenues in 2020, 2019 and 2018, respectively, were derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 18, Collaborative and Other Relationships, to these consolidated financial statements.
Other Revenues
Other revenues are summarized as follows:
 For the Years Ended December 31,
(In millions)202020192018
Revenues from collaborative and other relationships:
Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis$20.9 $106.2 $96.4 
Other revenues from collaborative and other relationships0.7 — (8.6)
Other royalty and corporate revenues:
Royalty33.9 17.0 38.7 
Other corporate719.1 584.5 459.4 
Total other revenues$774.6 $707.7 $585.9 
Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic customers, including Bioverativ Inc. (Bioverativ). During the years ended December 31, 2020, 2019 and 2018, we recognized $48.6 million, $383.2 million and $206.7 million, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.
During the third quarter of 2019, we amended our agreement with a contract manufacturing customer pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020, the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result we are entitled to $500.0 million in a series of three payments. The first payment became due upon a regulatory approval of such product and was received during the second quarter of 2020. Subsequent payments are due on the first and second anniversaries of the regulatory approval.
Other corporate revenues for the year ended December 31, 2020, reflect $346.2 million related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above and the performance of manufacturing product supply services for such customer. We have allocated the remaining $153.8 million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services.
For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 18, Collaborative and Other Relationships, to these consolidated financial statements.